Cellivery's Cytokine Storm Suppressing Drug 'iCP-NI'... "Confirmed Efficacy in Treating Pulmonary Fibrosis"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 13th that its cytokine storm suppressing severe sepsis treatment new drug 'iCP-NI', currently under development, has confirmed efficacy in suppressing pulmonary fibrosis caused by pneumonia. Along with this, verification of protective efficacy against immune cell destruction caused by the novel coronavirus infection (COVID-19), which has recently become an issue, has begun.

A representative from Cellivery's new drug development research institute stated, "In the evaluation of iCP-NI's therapeutic efficacy using over 2,000 animals so far, the mortality rate of 100% due to severe inflammation was improved to a 100% survival rate," adding, "It controls the production of all 20 types of inflammatory cytokines themselves, suppressing the cytokine storm and protecting major organs in the body."

He explained, "Recently, in a powerful acute pneumonia animal model simulating viral infection, iCP-NI not only prevented the collapse of lung tissue essential for breathing but also demonstrated lung function protective efficacy by preventing pulmonary fibrosis, which hardens the lungs and causes loss of lung function even after pneumonia is treated. This was proven through X-ray and CT scans as well as three different types of immunohistochemical staining methods."

Additionally, recent research findings have revealed that COVID-19 can destroy T cells, which play a role in removing pathogens and viruses among human immune cells. This aligns with frontline medical staff observations that COVID-19 can attack the entire immune system and its constituent immune cell groups similarly to the AIDS virus (HIV), which causes acquired immunodeficiency syndrome. Doctors reported that internal organ damage in bodies deceased from COVID-19 was similar to organ damage in patients who died from AIDS.

Meanwhile, Cellivery is currently evaluating the drug using large animals infected with the COVID-19 virus at a third-party specialized contract testing organization. The company emphasized, "Verification experiments to determine whether iCP-NI has therapeutic efficacy against immune cell destruction, newly reported as a lesion caused by COVID-19, are being immediately planned and conducted within Cellivery's research institute, and results will be produced quite rapidly," adding, "This experiment will also be included in the US COVID-19 non-human primate efficacy evaluation test items."

This content was produced with the assistance of AI translation services.